Rapamycin extends the lifespan of mice by 10–25%, while mutations in the insulin-like growth factor pathway double the lifespan of the nematode C. elegans. This difference is not coincidental: the more complex an organism, the less effective an intervention targeting a single molecular pathway becomes.
This paradox has been recognized for a long time. The very same evolutionarily conserved pathways — mTOR, IIS, and FOXO — are active in worms, flies, and mammals. However, while altering a single node in simple models can reshape nearly all physiology, the same signal encounters resistance from numerous parallel and feedback loops in mice, and even more so in humans.
Authors of a new theoretical model from Romania and Germany attribute this phenomenon to increasing network complexity. As the number of tissues and organs grows, so does redundancy, feedback, and cross-interactions.
The proportion of “aging” controlled by a single target significantly declines. Consequently, the system actively resists change to maintain homeostasis.
Tissue specialization further complicates matters. Suppressing mTOR, for instance, can be beneficial in some organs but detrimental in others; while it may slow cell proliferation, it can also impair wound healing or immune response. Improving a single tissue does not guarantee the rejuvenation of the entire organism.
Another mechanism at play is the “next weakest link” effect. Even if one major cause of death is eliminated, another will inevitably emerge as paramount. According to calculations, completely eradicating cancer mortality would only add an average of about three years to a person's life.
Pleiotropy further exacerbates this issue. Pathways that stimulate growth and reproduction also support regeneration while simultaneously increasing cancer risk.
By suppressing these pathways, we gain both benefits and new risks. While simple organisms can drastically reallocate resources between growth, reproduction, and tissue maintenance, mammals, with their costly specialized organs, no longer possess such flexibility.
The model can be condensed into a simple formula: maximum lifespan extension is proportional to the “leverage” of an individual pathway, divided by the “buffering capacity” of the entire system. As complexity increases, this leverage weakens, while buffering strengthens. Consequently, a single substance or mutation can no longer produce the same dramatic effect as before.
The authors' conclusion is predictable yet crucial: significantly impacting human aging will likely require multi-component interventions that simultaneously target multiple tissues and pathways. The search for a single “master switch” in complex organisms has, it appears, exhausted its potential.
